Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia

被引：3
|
作者：
Yusof, M. Md [1 ]
Cescon, D. W. [2 ]
Rugo, H. S. [3 ]
Im, S-A. [4 ]
Gallardo, C. [5 ]
Lipatov, O. [6 ]
Barrios, C. H. [7 ]
Holgado, E. [8 ,9 ,10 ]
Iwata, H. [11 ]
Masuda, N. [12 ]
Gokmen, E. [13 ]
Loi, S. [14 ]
Guo, Z. [15 ]
Jensen, E. [15 ]
Aktan, G. [16 ]
Karantza, V. [16 ]
Schmid, P. [17 ]
Cortes, J. [18 ,19 ,20 ,21 ]
机构：
[1] Pantai Hosp, Dept Oncol, Kuala Lumpur, Malaysia
[2] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Calif San Francisco, Dept Hematol Oncol, Ctr Comprehens Canc, San Francisco, CA 94143 USA
[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[5] Arturo Lopez Perez Fdn, Inst Oncol, Santiago, Chile
[6] Republican Clin Oncol Dispensary, Dept Oncol, Republic Bashkortostan, Russia
[7] Pontificia Univ Catolica Rio Grande do Sul, HSL, Ctr Pesquisa Oncol, Dept Med, Porto Alegre, RS, Brazil
[8] IOB Inst Oncol, Quironsalud Grp, Breast Canc Program, Madrid, Spain
[9] IOB Inst Oncol, Quironsalud Grp, Breast Canc Program, Barcelona, Spain
[10] Ramon & Cajal Univ Hosp, Madrid, Spain
[11] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan
[12] Osaka Natl Hosp, Natl Hosp Org, Dept Surg, Breast Oncol, Osaka, Japan
[13] Ege Univ, Dept Med Oncol, Med Fac, Izmir, Turkey
[14] Peter MacCallum Canc Inst, Dept Res & Canc Med, Melbourne, Vic, Australia
[15] Merck & Co Inc, Biostat, Kenilworth, NJ USA
[16] Merck & Co Inc, Oncol, Kenilworth, NJ USA
[17] Barts Canc Inst, Centre Expt Canc Med, London, England
[18] IOB Inst Oncol, Breast Canc Program, Quironsalud Grp, Madrid, Spain
[19] IOB Inst Oncol, Breast Canc Program, Quironsalud Grp, Barcelona, Spain
[20] Vall dHebron Inst Oncol, Madrid, Spain
[21] Vall dHebron Inst Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
430
引用
收藏
页码：S1257 / S1257
页数：1
相关论文
共 50 条
  • [41] Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.
    Merle, Philippe
    Edeline, Julien
    Bouattour, Mohamed
    Cheng, Ann-Lii
    Chan, Stephen Lam
    Yau, Thomas
    Garrido, Marcelo
    Knox, Jennifer J.
    Daniele, Bruno
    Zhu, Andrew X.
    Breder, Valeriy Vladimirovich
    Lim, Ho Yeong
    Ogasawara, Sadahisa
    Siegel, Abby B.
    Rahman, Ahmadur
    Wei Ziwen
    Finn, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [42] Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study
    Chung, Hyun Cheol
    Saada-Bouzid, Esma
    Longo, Federico
    Yanez, Eduardo
    Im, Seock-Ah
    Castanon, Eduardo
    Desautels, Danielle N.
    Graham, Donna M.
    Garcia-Corbacho, Javier
    Lopez, Juanita
    Dutcus, Corina
    Okpara, Chinyere E.
    Ghori, Razi
    Jin, Fan
    Groisberg, Roman
    Korakis, Iphigenie
    CANCER, 2024, 130 (19) : 3278 - 3288
  • [43] IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab plus chemo in early triple-negative breast cancer (TNBC)
    Saji, S.
    Mittendorf, E.
    Harbeck, N.
    Zhang, H.
    Barrios, C. H.
    Hegg, R.
    Koehler, A.
    Sohn, J.
    Iwata, H.
    Telli, M. L.
    Ferrario, C.
    Punie, K.
    Llorca, F. Penault
    Patel, S.
    Duc, A. Nguyen
    Hermoso, M. Liste
    Maiya, V.
    Molinero, L.
    Chui, S.
    Jung, K. H.
    ANNALS OF ONCOLOGY, 2020, 31 : S1243 - S1243
  • [44] COST-EFFECTIVENESS OF PEMBROLIZUMAB PLUS NAB-PACLITAXEL IN PREVIOUSLY UNTREATED LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER (TNBC) WHOSE TUMORS EXPRESSED PD-L1 (CPS ≥10) IN COLOMBIA
    Urrego-Reyes, J.
    Lopez, C.
    Marrugo, A. C.
    Velasco, J. S.
    Singla, P.
    Gotarkar, S.
    Huang, M.
    Haiderali, A.
    VALUE IN HEALTH, 2023, 26 (06) : S74 - S75
  • [45] A phase 2 study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation with pembrolizumab in patients with inoperable locally advanced or metastatic triple negative breast cancer
    Telli, M. L.
    Wapnir, I.
    Vinayak, S.
    Chang, J.
    Alemany, C.
    Twitty, C.
    Gargosky, S.
    CANCER RESEARCH, 2019, 79 (04)
  • [46] KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy (chemo), followed by adjuvant pembro or pbo plus endocrine therapy (ET) for early-stage high-risk ER+/HER2e breast cancer
    Cardoso, F.
    McArthur, H. L.
    Schmid, P.
    Cortes, J.
    Harbeck, N.
    Telli, M. L.
    Cescon, D. W.
    O'Shaughnessy, J.
    Fasching, P.
    Shao, Z.
    Loirat, D.
    Park, Y. H.
    Fernandez, M. E. Gonzalez
    Liu, Z.
    Yasojima, H.
    Ding, Y.
    Jia, L.
    Karantza, V. V.
    Tryfonidis, K. E.
    Bardia, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1260 - S1261
  • [47] Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro) plus chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial
    Loi, S.
    Schmid, P.
    Aktan, G.
    Karantza, V.
    Salgado, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [48] Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
    Adams, S.
    Loi, S.
    Toppmeyer, D.
    Cescon, D. W.
    De Laurentiis, M.
    Nanda, R.
    Winer, E. P.
    Mukai, H.
    Tamura, K.
    Armstrong, A.
    Liu, M. C.
    Iwata, H.
    Ryvo, L.
    Wimberger, P.
    Rugo, H. S.
    Tan, A. R.
    Jia, L.
    Ding, Y.
    Karantza, V.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2019, 30 (03) : 405 - 411
  • [49] Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162)
    Konstantinopoulos, P. A.
    Sachdev, J. C.
    Schwartzberg, L.
    Matulonis, U. A.
    Sun, P.
    Wang, J. Y.
    Guo, W.
    Bobilev, D.
    Aktan, G.
    Karantza, V.
    Dezube, B.
    Vinayak, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
    Maurer, C.
    Eiger, D.
    Velghe, C.
    Aftimos, P. G.
    Maetens, M.
    Gaye, J.
    Paesmans, M.
    Ignatiadis, M.
    Piccart, M.
    Buisseret, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 62 - 62
12345